Work

Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome

Year: 2017

Type: review

Abstract: INTRODUCTION: Inhibitors against the PD-1/PD-L1 pathway are revolutionizing the treatment and management of malignancies. AREAS COVERED: We summarize our current understanding of the function of PD-1, its role in immune evasion, the clinical data available that support the use of PD-1 antagonist in Hodgkin and non-Hodgkin lymphomas, and potential predictors of response. EXPERT OPINION: We anticipate that in the next 10 years, agents that modulate the immune system such as PD-1 antagonists will be increasingly used in favor over traditional cytotoxic chemotherapeutic agents. PD-1 antagonists will be combined with future immunotherapies or used as adjuncts to cellular therapy to boost tumor-specific immune responses.

Source: Expert Opinion on Investigational Drugs

DOI: 10.1080/13543784.2018.1416091

Authors: Andres Chang, Danielle Schlafer, Christopher R. Flowers, Pamela B. Allen

Institutions: Emory University, Winship Cancer Institute, Emory Healthcare

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Winship Cancer Institute, National Cancer Institute